IceCure Medical Ltd. — Form 6-K Summary
Reporting period: Report furnished October 5, 2026, covering an October 2026 development.
Business context and material development
IceCure develops and commercializes its ProSense system for cryoablation, including treatment of cancerous breast tumors. The company reported that the American Medical Association’s CPT Editorial Panel declined its request to replace the existing Category III code with a permanent Category I code, determining the transition was premature. The panel announced its decision on October 2, 2026, following review at its September 2026 meeting.
The decision does not change the temporary CPT Category III code. IceCure states that facilities can continue to receive approximately $4,000 in CMS facility-fee reimbursement for the ProSense procedure, and that the decision does not prevent the company from continuing commercial activities under the current reimbursement framework.
Financial and operating information
This 6-K does not report revenue, profit, cash flow, margins, debt, liquidity, or other period financial results. The approximately $4,000 figure is the stated facility fee for the procedure, not company revenue.
Outlook, risks, and unusual items
IceCure says the decision gives it additional time to expand clinical evidence, increase ProSense utilization, and work with medical societies. It identifies a potential resubmission of the Category I code request in June 2027; this is forward-looking and not assured. The filing cautions that actual results may differ materially and refers investors to risk factors in its 2025 Form 20-F and other SEC filings.
Important facts for investors to verify
- Whether IceCure resubmits the Category I code application in June 2027 and the outcome of any review.
- Whether clinical evidence, procedure utilization, and medical-society support increase sufficiently to support a future application.
- The continued availability and applicable terms of CMS facility-fee reimbursement under the Category III code.
- Any financial or commercial effects of the code decision, which this 6-K does not quantify.